US Representative
Nicholas Langworthy 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 9)
Legislative Session
Co-Sponsor of Legislation
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4369
Introduced
6/27/23
Refer
6/27/23
PANELS Act Protect Agriculture, Nutrients, and Essential Lands from Solar Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4438
Introduced
6/30/23
Refer
6/30/23
Refer
7/7/23
John W. Walsh Alpha-1 Home Infusion Act of 2023
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4468
Introduced
7/6/23
Refer
7/6/23
Refer
7/7/23
Report Pass
7/27/23
Engrossed
12/7/23
Choice in Automobile Retail Sales Act of 2023
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4563
Introduced
7/11/23
Refer
7/11/23
Refer
7/11/23
Report Pass
7/13/23
ACE Act End Zuckerbucks Act of 2023 Solving an Overlooked Loophole in Votes for Executives (SOLVE) Act Promoting Free and Fair Elections Act Don't Weaponize the IRS Act American Confidence in Elections Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4565
Introduced
7/11/23
Refer
7/11/23
ACE Act All Children are Equal Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB467
Introduced
1/24/23
Refer
1/24/23
Refer
1/24/23
Report Pass
3/24/23
Engrossed
5/30/23
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4713
Introduced
7/18/23
Refer
7/18/23
Refer
8/24/23
Rural Hospital Technical Assistance Program Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4721
Introduced
7/18/23
Refer
7/18/23
Main Street Tax Certainty Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4736
Introduced
7/19/23
Refer
7/19/23
Refer
8/24/23
Investing in Rural America Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4751
Introduced
7/19/23
Refer
7/19/23
No Taxpayer Funding For CZARS Act No Taxpayer Funding For Climate Zealots Advancing Radical Schemes Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4758
Introduced
7/19/23
Refer
7/19/23
Refer
7/21/23
Report Pass
6/12/24
Engrossed
9/18/24
Accelerating Kids’ Access to Care Act
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4891
Introduced
7/25/23
Refer
7/25/23
Multi-Cloud Innovation and Advancement Act of 2023
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4896
Introduced
7/26/23
Refer
7/26/23
Promotion and Expansion of Private Employee Ownership Act of 2023
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4927
Introduced
7/26/23
Refer
7/26/23
Refer
7/28/23
ACES Act of 2023 Anti-CCP Espionage via Social Media Act of 2023
US
Us Congress 2023-2024 Regular Session
Us Congress House Bill HB4945
Introduced
7/26/23
Refer
7/26/23
COTA Act Creating Opportunities to Thrive and Advance Act